Pharmaceutical

AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval

AlphaMedix is under clinical development by Orano Med and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).

Apr 23, 2024 - 00:00
AlphaMedix is under clinical development by Orano Med and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Read the original article

Tags:

Previous Article

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Next Article

Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe My...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: U.S. Chamber sues over Medicare price negotiations; FDA seeks new supplier for scarce cancer drug

STAT+: Pharmalittle: U.S. Chamber sues over Medicare pr...

Jun 12, 2023

Hong Kong approves Leqembi for Alzheimer’s treatment

Hong Kong approves Leqembi for Alzheimer’s treatment

Jul 12, 2024

Rankings

Oct 17, 2023